N-acetylcysteine (NAC): A precursor that supports natural glutathione production in the body
Newer medications specifically targeting NASH are in development, and some patients may be eligible for clinical trials
Simply resume the normal schedule with the next planned doseavoid "doubling up" to compensate
Documentation: Favor suppliers with transparent COAs , repeatable quality , and responsive support
If you try to do a study that says Im trying to get more mitochondria in my skeletal muscle, what exercise going to do it
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
)
